Sanofi

Equities

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris 11:35:24 2024-07-05 EDT 5-day change 1st Jan Change
90.94 EUR -0.07% Intraday chart for Sanofi +1.20% +1.31%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Sector Update: Health Care Stocks Steady Premarket Friday MT
Sector Update: Health Care MT
GlaxoSmithkline Pharmaceuticals Limited Announces Change in Management CI
Sanofi's Consumer Health Unit Receives Interest from French State MT
Bpifrance eyes investment in Sanofi's consumer health business RE
Bain Capital, Cinven, Others Said Mulling Bids for Sanofi's Consumer Health Unit MT
Bain, Cinven Explore Joint Bid for Sanofi's Consumer Unit, Bloomberg Reports DJ
Paul Hudson, CEO of Sanofi: AI to improve organisational efficiency MT
Bain, Cinven Said to Weigh Joint Bid for Sanofi's Consumer Health Division MT
Bain, Cinven Said to Weigh Joint Bid for Sanofi's Consumer Health Division MT
Bain, Cinven Said to Weigh Joint Bid for Sanofi's Consumer Health Division, Bloomberg Reports MT
SANOFI : Berenberg reiterates its Buy rating ZD
SANOFI : JP Morgan remains Neutral ZD
Delaware Judge Rejects Drugmakers' Appeal to End Zantac Lawsuits MT
Sanofi Blockbuster Drug Dupixent Gets First-in-World Approval in Europe for COPD MT
Regeneron, Sanofi Say Chronic Obstructive Pulmonary Disease Treatment Gains European Approval MT
Sanofi: approval of Dupixent for COPD in the EU CF
Sanofi obtains EU approval for Dupixent RE
Sanofi, Regeneron Get EU Approval for Dupixent to Treat Respiratory Disease DJ
Sanofi Wins EU Nod for Dupixent as Add-on Treatment for Chronic Obstructive Pulmonary Disease MT
EU approves Sanofi's Dupixent for 'smoker's lungs' RE
SANOFI SAYS DUPIXENT GRANTED EUROPEAN UNION APPROVAL TO TREAT… RE
Regeneron Pharmaceuticals, Inc. and Sanofi Announces Approval in the European Union as the First-Ever Targeted Therapy for Patients with COPD CI
Top Midday Stories: Tesla, GM Report Vehicle Deliveries; Biden, Sanders Say Novo Nordisk, Eli Lilly Charge 'Unconscionably' High Prices; Warner Bros. Interested in Deal With Paramount MT
SANOFI : Jefferies reaffirms its Buy rating ZD
Chart Sanofi
More charts
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
90.94 EUR
Average target price
108.1 EUR
Spread / Average Target
+18.86%
Consensus
  1. Stock Market
  2. Equities
  3. SAN Stock
  4. News Sanofi
  5. Sanofi Blockbuster Drug Dupixent Gets First-in-World Approval in Europe for COPD